- Idrabiotaparinux is a novel synthetic anticoagulant that links idraparinux, a specific, indirect factor Xa inhibitor, to biotin.
- Eplivanserin was being developed for insomnia.
Tuesday, December 22, 2009
Sanofi-Aventis ends development of idrabiotaparinux and eplivanserin
Sanofi-Aventis announced that it will stop the development of idrabiotaparinux and eplivanserin. Have you heard of these agents?
Labels: anticoagulation, cardiovascular, drug development, FDA, hematology, insomnia, sanofi-aventis
Subscribe to: Post Comments (Atom)
Post a Comment